Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors

Hitron, Anna; Steinke, Doug; Sutphin, Stephanie; Lawson, Amber; Talbert, Jeffery; Adams, Val R.

doi:10.1177/1078155210380293

Cited by 37 publications

(39 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer patients commonly have thrombocytopenia, either related to the underlying malignancy or to the cancer treatment 56. When they develop a CAT at the same time, the risk–benefit decisions are especially complex.…”

Section: Treatment Of Cancer‐associated Thrombosismentioning

confidence: 99%

Managing thrombosis in cancer patients

Wang

García

2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Venous thromboembolism is a major complication in cancer patients. The basis for the strong association between cancer and thrombosis remains incompletely understood, and the optimal approaches to both the treatment and the prevention of cancer‐associated thrombosis are evolving. Here we review several important topics related to cancer‐associated thromboembolism, including the pathogenesis, prevention, and management of this disease. Wherever possible, we include evidence from clinical trials, including the results of recently published trials that compared direct oral anticoagulants to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis.

show abstract

Section: Treatment Of Cancer‐associated Thrombosismentioning

confidence: 99%

Managing thrombosis in cancer patients

Wang

García

2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Additionally, chemotherapy-induced thrombocytopenia (CIT) is the most important cause of thrombocytopenia in patients with cancer [4]. Severe CIT not only has a risk of lifethreatening hemorrhagic complications but also may necessitate dose reduction and/or delay in chemotherapy schedules [3,[5][6][7][8]. Previous studies have indicated that various factors, such as platinum-based regimen, multiple high-risk chemotherapy treatments, multiple primary tumors, patients with lung cancer, and baseline thrombocyte count, have a high predictive value for CIT (3).…”

Section: Introductionmentioning

confidence: 99%

“…However, the underlying etiopathogenic mechanisms of chemotherapyrelated myelosuppression are not yet clear [1][2][3]. Additionally, chemotherapy-induced thrombocytopenia (CIT) is the most important cause of thrombocytopenia in patients with cancer [4].…”

Section: Introductionmentioning

confidence: 99%

Is there a predictive significance of ABO blood group on chemotherapy-induced thrombocytopenia in patients with stage III colon cancer?

Tanrıverdi

2014

Med Oncol

View full text Add to dashboard Cite

Chemotherapy-induced thrombocytopenia (CIT) is the most important cause of thrombocytopenia in cancer patients. In this paper, I discussed the effect of ABO blood group on CIT in patients with stage III colon cancer. In a pilot study, a total of 131 (72 men, 55 %) eligible patients with stage III colon cancer were divided into two groups according to whether they had CIT. Both groups were compared using demographic, histopathological, and laboratory variables. CIT was detected in 51 (40 %) of 131 patients. The incidence of CIT had a significant increased in patients with 0 blood group compared to other blood groups. It was concluded that the relationship between blood group 0 and the presence of CIT in patients with stage III colon cancer is independent of other study variables (P = 0.035, OR 3.14, 95 % CI 1.16-7.01). In conclusion, I hypothesized that 0 blood group may predict to differentiate high-risk patients for CIT.

show abstract

“…Chemotherapy-induced thrombocytopenia (CIT) is the most important cause of thrombocytopenia in patients with cancer (Hitron et al, 2011). However, the underlying etiopathogenic mechanisms of chemotherapyrelated myelosuppression are not yet clear (Levin et al, 2010;Bartucci et al, 2011;Ten et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Predictive Value of Baseline Plasma D-dimers for Chemotherapy-induced Thrombocytopenia in Patients with Stage III Colon Cancer: A Pilot Study

Tanrıverdi

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors

Abstract: The incidence of clinically significant CIT is most commonly seen in patients using cisplatin/gemcitabine for bladder cancer, or carboplatin/gemcitabine or cisplatin/etoposide for lung cancer. Further evaluation of these patients is warranted.

Cited by 37 publications

References 21 publications

Managing thrombosis in cancer patients

Managing thrombosis in cancer patients

Is there a predictive significance of ABO blood group on chemotherapy-induced thrombocytopenia in patients with stage III colon cancer?

Predictive Value of Baseline Plasma D-dimers for Chemotherapy-induced Thrombocytopenia in Patients with Stage III Colon Cancer: A Pilot Study

Contact Info

Product

Resources

About